Evidence map›Paper›PMID 26556577›Full record

Trial reportClinical oral investigations2016

Enamel matrix protein derivative and/or synthetic bone substitute for the treatment of mandibular class II buccal furcation defects. A 12-month randomized clinical trial.

Lucas Araujo Queiroz, Mauro Pedrine Santamaria, Marcio Z Casati, Karina Silverio Ruiz, Francisco Nociti, Antonio Wilson Sallum, Enilson A Sallum

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical oral investigations, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lucas Araujo QueirozFaculty of Odontology of Piracicaba, Piracicaba, São Paulo, Brazil.
Mauro Pedrine SantamariaFaculty of Odontology of Piracicaba, Piracicaba, São Paulo, Brazil.
Marcio Z CasatiFaculty of Odontology of Piracicaba, Piracicaba, São Paulo, Brazil.
Karina Silverio RuizFaculty of Odontology of Piracicaba, Piracicaba, São Paulo, Brazil.
Francisco NocitiFaculty of Odontology of Piracicaba, Piracicaba, São Paulo, Brazil.
Antonio Wilson SallumFaculty of Odontology of Piracicaba, Piracicaba, São Paulo, Brazil.
Enilson A SallumFaculty of Odontology of Piracicaba, Piracicaba, São Paulo, Brazil. easallum@fop.unicamp.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aims to clinically evaluate the treatment of mandibular class II furcation defects with enamel matrix derivative (EMD) and/or a bone substitute graft made of β-tricalcium phosphate/hydroxyapatite (βTCP/HA). MATERIALS AND

methodsForty-one patients, presenting a mandibular class II buccal furcation defect, probing pocket depth (PPD) ≥4 mm and bleeding on probing, were included. They were randomly assigned to the groups: 1-EMD (n = 13); 2-βTCP/HA (n = 14); 3-EMD + βTCP/HA (n = 14). Plaque index (PI), gingival index (GI), relative gingival margin position (RGMP), relative vertical and horizontal attachment level (RVCAL and RHCAL), and PPD were evaluated at baseline and 6 and 12 months. The mean horizontal clinical attachment level gain was considered the primary outcome variable.

resultsNo significant intragroup differences were observed for RGMP, but significant changes were observed for RVCAL, RHCAL, and PPD for all groups (p < 0.05). After 12 months, the mean horizontal clinical attachment level gain was 2.77 ± 0.93 mm for EMD, 2.64 ± 0.93 mm for βTCP/HA, and 2.93 ± 0.83 mm for EMD + βTCP/HA, with no significant differences among the groups. At the end of the study, 85.3 % of the sites were partially closed; however, no complete closure was observed.

conclusionEMD + βTCP/HA does not provide a significant advantage when compared to the isolated approaches. All three tested treatments promote significant improvements and partial closure of class II buccal furcation defects. Based on its potential to induce periodontal regeneration, EMD may be considered an attractive option for this type of defect, but complete closure remains an unrealistic goal. CLINICAL RELEVANCE: The partial closure of buccal furcation defects can be achieved after the three tested approaches. However, the combined treatment does not provide a significant benefit when compared to the isolated approaches.

Indexed as

Bone SubstitutesDental Enamel ProteinsDental Plaque IndexFemaleFurcation DefectsHumansHydroxyapatitesMaleMandibleMiddle AgedPeriodontal IndexSurgical FlapsTreatment OutcomeBoneCeramicBone SubstitutesDental Enamel Proteinsenamel matrix proteinshydroxyapatite-beta tricalcium phosphateHydroxyapatitesEnamel matrix proteinFurcation defectsHydroxyapatite-beta tricalcium phosphatePeriodontal diseaseRandomized controlled trial

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.